Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study Posted byZacks Equity Research November 30, 2021 Leave a comment on Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.